NZ562772A - Tricyclic spiro derivatives as CRTH2 modulators - Google Patents

Tricyclic spiro derivatives as CRTH2 modulators

Info

Publication number
NZ562772A
NZ562772A NZ562772A NZ56277206A NZ562772A NZ 562772 A NZ562772 A NZ 562772A NZ 562772 A NZ562772 A NZ 562772A NZ 56277206 A NZ56277206 A NZ 56277206A NZ 562772 A NZ562772 A NZ 562772A
Authority
NZ
New Zealand
Prior art keywords
chloro
pyrrolidin
indole
trioxospiro
acetic acid
Prior art date
Application number
NZ562772A
Other languages
English (en)
Inventor
Matthias Schwarz
Eric Sebille
Christophe Cleva
Cedric Merlot
Dennis Chruch
Patrick Page
Jacqueline A Macritchie
John Frederick Atherall
Stefano Crosignani
Doris Pupowicz
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NZ562772A publication Critical patent/NZ562772A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ562772A 2005-05-24 2006-05-23 Tricyclic spiro derivatives as CRTH2 modulators NZ562772A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05104428 2005-05-24
US68863105P 2005-06-08 2005-06-08
PCT/EP2006/062545 WO2006125784A1 (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as crth2 modulators

Publications (1)

Publication Number Publication Date
NZ562772A true NZ562772A (en) 2010-01-29

Family

ID=35478408

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ562772A NZ562772A (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as CRTH2 modulators

Country Status (20)

Country Link
US (1) US8236963B2 (OSRAM)
EP (1) EP1891075B1 (OSRAM)
JP (1) JP5567268B2 (OSRAM)
KR (1) KR101333861B1 (OSRAM)
CN (1) CN101300259B (OSRAM)
AR (1) AR055959A1 (OSRAM)
AT (1) ATE529429T1 (OSRAM)
AU (1) AU2006251138C1 (OSRAM)
BR (1) BRPI0610209A2 (OSRAM)
CA (1) CA2602965C (OSRAM)
DK (1) DK1891075T3 (OSRAM)
ES (1) ES2375614T3 (OSRAM)
MX (1) MX2007014256A (OSRAM)
NZ (1) NZ562772A (OSRAM)
PL (1) PL1891075T3 (OSRAM)
PT (1) PT1891075E (OSRAM)
RU (1) RU2478639C2 (OSRAM)
UA (1) UA90145C2 (OSRAM)
WO (1) WO2006125784A1 (OSRAM)
ZA (1) ZA200709819B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658986C (en) 2006-08-07 2014-11-25 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
US20120115895A1 (en) 2009-07-15 2012-05-10 Merck Serono S.A. Tricyclic indole-derived spiro derivatives as crth2 modulators
BR112012011317A2 (pt) 2009-11-12 2019-09-24 Univ Michigan Regents antagonistas espiro-oxindóis de mdm2
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
AU2011326395B2 (en) 2010-11-12 2016-01-07 Ascenta Licensing Corporation Spiro-oxindole MDM2 antagonists
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 7−(ヘテロアリ−ル−アミノ)−6,7,8,9−テトラヒドロピリド[1,2−a]インド−ル酢酸誘導体及びプロスタグランジンD2受容体調節剤としてのそれらの使用
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールmdm2アンタゴニスト
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
TWI649321B (zh) 2014-03-17 2019-02-01 瑞士商愛杜西亞製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素d2受體調節劑之用途
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CA2979391C (en) 2015-03-13 2023-10-17 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as hdac8 inhibitors
LT3322701T (lt) 2015-07-15 2019-07-10 F. Hoffmann-La Roche Ag Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
RU2631856C1 (ru) * 2016-05-04 2017-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения аммонийных солей 3-амино-8-гидрокси-1,6-диоксо-4-циано-2,7-диазаспиро[4.4]нон-3-ен-2-идов
JP6936305B2 (ja) 2016-07-18 2021-09-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft エチニル誘導体
CN109384787B (zh) * 2017-08-08 2021-04-16 沈阳药科大学 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
CN109384794B (zh) * 2017-08-08 2020-06-19 沈阳药科大学 质子酸催化的一类四环吲哚骨架的合成方法
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
WO2020140054A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52879B1 (en) 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
IE53102B1 (en) 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
US5948807A (en) 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
HUP0202248A3 (en) * 1999-03-12 2006-06-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
EP1556047A4 (en) 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
MXPA05003660A (es) 2002-10-21 2005-06-08 Warner Lambert Co Derivados de quinolina como antagonistas de crth2.
ATE316077T1 (de) 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
WO2005007094A2 (en) 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
WO2005102338A1 (en) 2004-04-20 2005-11-03 Pfizer Limited Method of treating neuropathic pain using a crth2 receptor antagonist

Also Published As

Publication number Publication date
CA2602965C (en) 2013-12-31
AU2006251138B2 (en) 2012-08-09
US8236963B2 (en) 2012-08-07
CN101300259B (zh) 2013-08-28
KR101333861B1 (ko) 2013-11-28
CA2602965A1 (en) 2006-11-30
UA90145C2 (ru) 2010-04-12
KR20080031191A (ko) 2008-04-08
RU2478639C2 (ru) 2013-04-10
WO2006125784A1 (en) 2006-11-30
ATE529429T1 (de) 2011-11-15
AU2006251138C1 (en) 2013-08-29
AR055959A1 (es) 2007-09-12
DK1891075T3 (da) 2011-12-19
ZA200709819B (en) 2009-09-30
AU2006251138A1 (en) 2006-11-30
PT1891075E (pt) 2011-11-10
EP1891075B1 (en) 2011-10-19
JP2008542238A (ja) 2008-11-27
RU2007147430A (ru) 2009-06-27
MX2007014256A (es) 2008-03-26
US20090318486A1 (en) 2009-12-24
JP5567268B2 (ja) 2014-08-06
PL1891075T3 (pl) 2011-12-30
EP1891075A1 (en) 2008-02-27
CN101300259A (zh) 2008-11-05
BRPI0610209A2 (pt) 2010-06-01
ES2375614T3 (es) 2012-03-02

Similar Documents

Publication Publication Date Title
EP1891075B1 (en) Tricyclic spiro derivatives as crth2 modulators
CA2691776C (en) Substituted imidazoheterocycles
JP6116245B2 (ja) 神経変性疾患治療における使用のためのインドールアミン誘導体および関連化合物
JP5580330B2 (ja) Vegf−r2のピリジルオキシインドール類阻害剤および疾患の処置のためのその使用
RS52175B (sr) Hidroksimetil pirolidini kao agonisti beta 3 adrenergičkog receptora
JP2024522827A (ja) Cbl-b調節因子及びその使用
TW202019408A (zh) 稠合三環雜環化合物及其治療用途
KR20110106450A (ko) 바이시클릭 피라졸로-헤테로사이클
JP2024514847A (ja) Cbl-b修飾因子及びその使用
US8835422B2 (en) Substituted imidazoheterocycle derivatives
US8859538B2 (en) Uses of substituted imidazoheterocycles
CN119855589A (zh) 杂环pad4抑制剂
HK1121146A1 (en) Tricyclic spiro derivatives as crth2 modulators
HK1121146B (en) Tricyclic spiro derivatives as crth2 modulators
JP2022521895A (ja) ファルネソイドx受容体モジュレータとしての置換二環式化合物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 MAY 2016 BY CPA GLOBAL

Effective date: 20130412

LAPS Patent lapsed